

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

COALITION FOR AFFORDABLE DRUGS (ADROCA) LLC,  
Petitioner,

v.

ACORDA THERAPEUTICS, INC.,  
Patent Owner.

---

Case IPR2015-00720  
Patent 8,663,685 B2

---

Before MICHAEL P. TIERNEY, LORA M. GREEN, and  
JACQUELINE WRIGHT BONILLA, *Administrative Patent Judges*.

BONILLA, *Administrative Patent Judge*.

DECISION  
Denying Institution of *Inter Partes* Review  
*37 C.F.R. § 42.108*

## I. INTRODUCTION

Coalition For Affordable Drugs (ADROCA) LLC (“Petitioner”) filed a Corrected Petition requesting an *inter partes* review of claims 1–8 of U.S. Patent No. 8,663,685 B2 (Ex. 1001, “the ’685 patent”). Paper 7 (“Petition” or “Pet.”). Acorda Therapeutics, Inc. (“Patent Owner”) filed a Preliminary Response to the Petition. Paper 10 (“Prelim. Resp.”).

Petitioner advances three grounds of unpatentability under 35 U.S.C. § 103(a) in relation to the challenged claims in the ’685 patent. Pet. 13–14. All three grounds rely on the Goodman poster (Ex. 1008),<sup>1</sup> and one ground further relies on the Hayes poster (Ex. 1009).<sup>2</sup> For the reasons discussed below, we are not persuaded that Petitioner has shown that the Goodman and Hayes posters constitute prior art to the ’685 patent. Petitioner, therefore, has not established that there is a reasonable likelihood that it would prevail with respect to at least one of the claims challenged in the Petition, as required under 35 U.S.C. § 314(a).

---

<sup>1</sup> Goodman et al., poster titled “*Placebo-Controlled Double-Blinded Dose Ranging Study of Fampridine-SR in Multiple Sclerosis*” (7th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and 18th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS/ECTRIMS), Baltimore, MD, September 18–21, 2002) (“the Goodman poster”) (Ex. 1008). *See also* Ex. 2033, 3 (“C416”).

<sup>2</sup> Hayes et al., poster titled “*Open-Label, Multiple-Dose Study to Determine the Pharmacokinetics and Safety of Fampridine-SR (Sustained-Release 4-Aminopyridine) in Patients with Chronic Spinal Cord Injury*” (American Neurological Association, Chicago, IL, September 30–October 3, 2001) (“the Hayes poster”) (Ex. 1009). *See also* Ex. 2031, 12 (“C148”).

## II. ANALYSIS

Petitioner asserts that the Goodman poster “constitutes prior art under 35 U.S.C. § 102(b) because it was published at least as early as September 18–21, 2002 (a fact admitted by the ’685 patent applicants in an October 1, 2012 IDS, see Ex. 1043, at Reference No. C416).” Pet. 18. Petitioner also contends that the Hayes poster “constitutes prior art under 35 U.S.C. § 102(b) because it was published on Sept. 30–October 3, 2001, more than one year prior to December 11, 2003 (a fact admitted by the ’685 patent applicants in an October 31, 2011 IDS, see Ex. 1033, at Reference No. C148).” *Id.* at 19. Exhibits 1043 and 1033 present portions of Information Disclosure Statements (“IDSs”) for Application No. 13/187,158 (“the ’158 application”), which issued as the ’685 patent.

Patent Owner acknowledges that relevant IDSs submitted during prosecution of the ’158 application state that the Goodman and Hayes posters “were ‘presented.’” Prelim. Resp. 11–12 (citing Ex. 2033, 3, “C416”; Ex. 2031, 12, “C148”). Patent Owner contends, however, that “even if Petitioner claims that the posters were displayed at meetings, this does not establish that the posters are printed publications” that qualify as prior art under § 102. *Id.* at 12 (citing *In re Klopfenstein*, 380 F.3d 1345, 1349 n.4 (Fed. Cir. 2004)). We agree.

First, the submission of an IDS does not constitute an admission that a cited reference is material prior art. *ResQNet.com, Inc. v. Lansa, Inc.*, 594 F.3d 860, 866 (Fed. Cir. 2010); *Abbott Labs. v. Baxter Pharm. Prods., Inc.*, 334 F.3d 1274, 1279 (Fed. Cir. 2003)); *see also* 37 C.F.R. § 1.97(h) (stating that the filing of an IDS “shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to

patentability as defined in § 1.56(b)”). Moreover, in this case, the relevant IDSs themselves state expressly that “[i]dentification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as ‘prior art’ against the subject application.” Prelim. Resp. 19 (quoting Ex. 2031, 2; Ex. 2033, 1).

Second, as also noted by Patent Owner, a “determination of whether a reference is a ‘printed publication’ under 35 U.S.C. § 102(b) involves a case-by-case inquiry into the facts and circumstances surrounding the reference’s disclosure to members of the public.” *Klopfenstein*, 380 F.3d at 1350; Prelim. Resp. 12–18. Several factors “aid in resolving whether or not a temporarily displayed reference that was neither distributed nor indexed was nonetheless made sufficiently publicly accessible to count as a ‘printed publication’ under § 102(b).” *Klopfenstein*, 380 F.3d at 1350. Because Petitioner does not indicate that the Goodman and Hayes posters were distributed (rather than presented) or indexed, we consider those factors now, which include: “[1] the length of time the display was exhibited, [2] the expertise of the target audience, [3] the existence (or lack thereof) of reasonable expectations that the material displayed would not be copied, and [4] the simplicity or ease with which the material displayed could have been copied.” *Id.*

The “duration of the display is important in determining the opportunity of the public in capturing, processing and retaining the information conveyed by the reference.” *Id.* Along those lines, “[t]he more transient the display, the less likely it is to be considered a ‘printed publication.’” *Id.* at 1350–51. Here, we agree with Patent Owner that Petitioner presents insufficient evidence as to how long the Goodman or

Hayes poster was presented at any scientific meeting. Prelim. Resp. 13–14. The only credible evidence of record indicating that the posters were presented at all is in the form of IDSs stating that the posters were “presented.”

Similarly, Petitioner presents insufficient evidence in relation to “the expertise of the target audience,” i.e., anyone who actually saw either poster. *Id.* at 14–15. Petitioner likewise presents insufficient evidence in relation to any reasonable expectation that one could have copied the poster material, or evidence regarding the ease with which the poster material could have been copied. *Id.* at 15–16. Overall, evidence of record fails to demonstrate that the posters nonetheless were made sufficiently publicly accessible. For example, evidence of record does not indicate adequately how long the posters were presented to anyone, or to whom exactly, or what conversations anyone might have had with authors about the posters.

In addition, our review of the posters themselves indicates that they both present relatively dense material in a small space. Ex. 1008, 2; Ex. 1009, 1. As stated by the Federal Circuit, the “more complex a display, the more difficult it will be for members of the public to effectively capture its information.” *Klopfenstein*, 380 F.3d at 1351.

We are not persuaded that Petitioner has made a threshold showing that the posters were sufficiently publicly accessible to qualify as a “printed publication” under § 102(b). Petitioner has not demonstrated adequately that the Goodman poster (relied upon in all grounds) or the Hayes poster, as presented in the Petition, constitute prior art to the ’685 patent.

IPR2015-00720  
Patent 8,663,685 B2

III. ORDER

It is

ORDERED that the Petition is denied as to all challenged claims and no trial is instituted.

IPR2015-00720  
Patent 8,663,685 B2

For PETITIONER:

Sarah Spires  
Parvathi Kota  
Paul Skiermont  
Skiermont Puckett LLP  
Ki.O@SkiermontPuckett.com  
sarah.spires@skiermontpuckett.com  
parvathi.kota@skiermontpuckett.com

For PATENT OWNER:

Gerald Flattmann  
Naveen Modi  
Paul Hastings LLP  
acorda-685patent@paulhastings.com